B-condition	0	18	Neuropsychological
I-condition	19	30	functioning
O	31	33	in
O	34	48	postmenopausal
O	49	55	breast
O	56	62	cancer
O	63	71	patients
O	72	79	treated
O	80	84	with
B-intervention	85	94	tamoxifen
I-intervention	95	97	or
I-intervention	98	108	exemestane
O	109	114	after
O	115	117	AC
O	117	118	-
O	118	130	chemotherapy
O	130	131	:
O	132	137	cross
O	137	138	-
O	138	147	sectional
O	148	156	findings
O	157	161	from
O	162	165	the
O	166	184	neuropsychological
O	185	189	TEAM
O	189	190	-
O	190	194	side
O	195	200	study
O	200	201	.

O	202	210	Previous
O	211	218	studies
O	219	223	have
O	224	233	indicated
O	234	238	that
O	239	240	a
O	241	247	subset
O	248	250	of
O	251	257	cancer
O	258	266	patients
O	267	274	treated
O	275	279	with
O	280	292	chemotherapy
O	293	297	show
O	298	307	cognitive
O	308	316	deficits
O	317	320	and
O	320	321	/
O	321	323	or
O	324	334	experience
O	335	344	cognitive
O	345	355	complaints
O	355	356	,
O	357	364	whereas
O	365	375	literature
O	376	381	about
O	382	385	the
O	386	395	influence
O	396	398	of
O	399	407	hormonal
O	408	417	therapies
O	418	420	on
O	421	430	cognition
O	431	433	is
O	434	440	sparse
O	440	441	.

O	442	449	Because
O	450	452	of
O	453	456	the
O	457	469	accumulating
O	470	479	knowledge
O	480	485	about
O	486	489	the
O	490	500	importance
O	501	503	of
O	504	512	estrogen
O	513	516	for
O	517	526	cognitive
O	527	538	functioning
O	538	539	,
O	540	545	there
O	546	548	is
O	549	556	growing
O	557	564	concern
O	565	570	about
O	571	579	adjuvant
O	580	588	hormonal
O	589	596	therapy
O	597	600	for
O	601	607	breast
O	608	614	cancer
O	615	616	(
O	616	618	BC
O	618	619	)
O	620	629	affecting
O	630	639	cognition
O	639	640	.

O	641	643	We
O	644	652	examined
O	653	656	the
O	657	666	cognitive
O	667	678	functioning
O	679	681	of
B-eligibility	682	696	postmenopausal
I-eligibility	697	699	BC
I-eligibility	700	708	patients
I-eligibility	709	712	who
I-eligibility	713	717	were
I-eligibility	717	718	,
I-eligibility	719	728	following
I-eligibility	729	740	doxorubicin
I-eligibility	740	741	/
I-eligibility	741	757	cyclophosphamide
I-eligibility	758	759	(
I-eligibility	759	761	AC
I-eligibility	761	762	)
I-eligibility	763	775	chemotherapy
O	775	776	,
O	777	787	randomized
O	788	790	to
O	791	800	tamoxifen
O	801	803	or
O	804	814	exemestane
O	814	815	,
O	816	819	and
O	820	828	compared
O	829	834	their
O	835	846	performance
O	847	851	with
O	852	856	that
O	857	859	of
O	860	863	non
O	863	864	-
O	864	870	cancer
O	871	879	controls
O	879	880	.

B-intervention-participants	881	887	Thirty
O	888	890	BC
O	891	899	patients
O	900	905	using
O	906	915	tamoxifen
O	916	919	and
B-intervention-participants	920	922	50
O	923	931	patients
O	932	937	using
O	938	948	exemestane
O	949	958	underwent
O	959	969	interviews
O	969	970	,
O	971	985	questionnaires
O	986	989	and
O	990	999	cognitive
O	1000	1005	tests
O	1005	1006	,
O	1007	1009	on
O	1010	1017	average
O	1018	1021	two
O	1022	1027	years
O	1028	1033	after
O	1034	1044	completion
O	1045	1047	of
O	1048	1050	AC
O	1051	1063	chemotherapy
O	1063	1064	.

B-control-participants	1065	1070	Forty
I-control-participants	1071	1076	eight
B-control	1077	1084	healthy
I-control	1085	1093	controls
O	1094	1098	were
O	1099	1105	tested
O	1106	1110	with
O	1111	1118	similar
O	1119	1127	measures
O	1127	1128	.

B-outcome	1129	1135	Memory
I-outcome	1136	1146	complaints
O	1147	1151	were
O	1152	1160	reported
O	1161	1163	by
B-iv-bin-percent	1164	1166	28
I-iv-bin-percent	1166	1167	%
O	1168	1170	of
O	1171	1173	AC
O	1173	1174	/
O	1174	1183	tamoxifen
O	1184	1189	users
O	1189	1190	,
B-iv-bin-percent	1191	1193	24
I-iv-bin-percent	1193	1194	%
O	1195	1197	of
O	1198	1200	AC
O	1200	1201	/
O	1201	1211	exemestane
O	1212	1217	users
O	1218	1221	and
B-cv-bin-percent	1222	1223	6
I-cv-bin-percent	1223	1224	%
O	1225	1227	of
O	1228	1235	healthy
O	1236	1244	controls
O	1245	1246	(
O	1246	1247	p
O	1247	1248	=
O	1248	1249	0
O	1249	1250	.
O	1250	1252	02
O	1252	1253	)
O	1253	1254	.

O	1255	1264	Cognitive
O	1265	1272	testing
O	1273	1281	revealed
O	1282	1284	no
O	1285	1298	statistically
O	1299	1310	significant
O	1311	1322	differences
O	1323	1330	between
O	1331	1340	tamoxifen
O	1341	1344	and
O	1345	1355	exemestane
O	1356	1361	users
O	1361	1362	,
O	1363	1366	but
O	1367	1376	suggested
O	1377	1381	that
O	1382	1391	tamoxifen
O	1392	1395	use
O	1396	1398	is
O	1399	1407	possibly
O	1408	1415	related
O	1416	1418	to
O	1419	1424	worse
B-outcome	1425	1431	verbal
I-outcome	1432	1443	functioning
O	1443	1444	,
O	1445	1450	while
O	1451	1461	exemestane
O	1462	1465	use
O	1466	1468	is
O	1469	1477	possibly
O	1478	1485	related
O	1486	1488	to
O	1489	1495	slower
O	1496	1502	manual
B-outcome	1503	1508	motor
I-outcome	1509	1514	speed
O	1514	1515	.

O	1516	1520	Both
O	1521	1528	patient
O	1529	1535	groups
O	1536	1545	performed
O	1546	1559	significantly
O	1560	1565	worse
O	1566	1570	than
O	1571	1578	healthy
O	1579	1587	controls
O	1588	1590	on
B-outcome	1591	1597	verbal
I-outcome	1598	1605	fluency
O	1606	1609	and
B-outcome	1610	1621	information
I-outcome	1622	1632	processing
I-outcome	1633	1638	speed
O	1638	1639	.

O	1640	1643	Our
O	1644	1652	findings
O	1653	1657	show
O	1658	1662	that
O	1663	1673	sequential
O	1674	1683	treatment
O	1684	1686	of
O	1687	1689	AC
O	1689	1690	-
O	1690	1702	chemotherapy
O	1703	1706	and
O	1707	1715	hormonal
O	1716	1723	therapy
O	1724	1726	in
O	1727	1741	postmenopausal
O	1741	1742	,
O	1743	1750	primary
O	1751	1753	BC
O	1754	1756	is
O	1757	1767	associated
O	1768	1772	with
O	1773	1778	lower
O	1779	1783	test
O	1784	1790	scores
O	1791	1794	for
O	1795	1802	certain
O	1803	1812	cognitive
O	1813	1822	functions
O	1822	1823	,
O	1824	1827	and
O	1828	1835	provide
O	1836	1847	indications
O	1848	1851	for
O	1852	1860	possibly
O	1861	1872	distinctive
O	1873	1885	associations
O	1886	1889	for
O	1890	1899	different
O	1900	1905	types
O	1906	1908	of
O	1909	1917	hormonal
O	1918	1927	treatment
O	1927	1928	.

O	1929	1935	Future
O	1936	1944	research
O	1945	1949	with
O	1950	1956	larger
O	1957	1963	groups
O	1964	1966	is
O	1967	1978	recommended
O	1979	1981	to
O	1982	1988	obtain
O	1989	1990	a
O	1991	1995	more
O	1996	2004	definite
O	2005	2012	picture
O	2012	2013	.
